Silence Therapeutics plc
NASDAQ: SLN0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Iain Gladstone Ross
- Employees
- 116
- Headquarters
- London, United Kingdom
- IPO year
- 2020
- Market cap
- $432.7M
- Website
- https://www.silence-therapeutics.com
Loading SLN…
Loading profile data…Frequently asked questions about SLN
What does Silence Therapeutics plc (SLN) do?
Silence Therapeutics plc is a London, UK-based biotechnology company specializing in the research and development of groundbreaking ribonucleic acid (RNA) therapeutics. Its therapeutic focus areas include hematological, cardiovascular, and various rare and metabolic conditions. Central to their innovative approach is the mRNAi GalNAc Oligonucleo...
Where does SLN trade?
Silence Therapeutics plc (SLN) trades on the NASDAQ Global Market.
What sector is SLN in?
Silence Therapeutics plc (SLN) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Silence Therapeutics plc?
Iain Gladstone Ross is the chief executive officer of Silence Therapeutics plc (SLN).
Where is Silence Therapeutics plc headquartered?
Silence Therapeutics plc is headquartered in United Kingdom.
Does SLN pay a dividend?
Silence Therapeutics plc (SLN) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did SLN go public?
Silence Therapeutics plc (SLN) completed its initial public offering in 2020.
Is SLN an ADR?
Yes — SLN is an American Depositary Receipt; its underlying shares trade on a non-US exchange. Silence Therapeutics plc reporting and dividends follow the underlying issuer.